December 2022

The Hunt for Novel Therapeutics Through Antibody Engineering

2022-12-02T11:22:32-05:00December 2nd, 2022|Articles|

Written by Genya Gorshtein, MSc November 1, 2022 Contents Introduction Approaches for Engineering Antibody Therapeutics Driving Antibody Engineering with Next Generation Protein Sequencing and Proteomics Introduction Antibody engineering encompasses various development, production strategies, and modification techniques to improve the biological properties of monoclonal antibodies (mAbs) as therapeutic [...]

Cell Specific Protein Degradation with Antibody Conjugated PROTACs

2022-12-02T10:23:52-05:00December 2nd, 2022|Articles|

Written by Genya Gorshtein, MSc November 25, 2022 Contents Introduction General PROTAC Structure and Function Antibody-Conjugated PROTACs Developing AbPROTACs with De Novo Antibody Sequencing and Proteomics Introduction Small-molecule drug development is aimed at inhibiting disease-promoting protein function through occupancy-driven protein inhibition. A major caveat of this therapeutic [...]

September 2022

Antibody Drug Conjugates as Anti-Cancer Therapeutics

2022-11-17T13:44:08-05:00September 19th, 2022|Articles|

Written by Genya Gorshtein, MSc September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer Chemotherapeutics Key Components of ADCs Future Generation of ADCs De Novo Protein Sequencing Applications in ADC Development Introduction An antibody-drug conjugate (ADC) is a monoclonal antibody (mAb) with a covalently attached cytotoxic payload [...]

August 2022

What are Polyclonal Antibodies?

2022-11-17T13:24:32-05:00August 18th, 2022|Articles|

Written by Genya Gorshtein, MSc August 18, 2022 Contents Introduction How are Polyclonal Antibodies Produced? Applications of Polyclonal Antibodies Challenges of Polyclonal Antibodies De Novo Polyclonal Antibody Sequencing Introduction Polyclonal antibodies (pAbs) are a heterogeneous mix of antibodies derived from B cells in the adaptive immune system. [...]

June 2022

April 2022

Broadly Neutralizing Antibody Cocktails Targeting Nipah Virus and Hendra Virus Fusion Glycoproteins

2022-10-05T14:14:55-04:00April 29th, 2022|Case Studies|

Hendra virus (HeV) and Nipah virus (NiV) are types of Henipaviruses (HNVs) that originated in bats and can infect the human respiratory system with detrimental consequences. As enveloped, single-stranded RNA viruses, HeV and NiV use attachment (G) and fusion (F) glycoproteins on the envelope membrane to enter host cells. So far, there are no approved therapeutics or vaccines to combat the viruses in humans.

February 2022

Camelid Antibodies and Nanobodies

2022-11-17T14:09:21-05:00February 4th, 2022|Articles|

Written by Yuning Wang, PhD January 21, 2022 Contents Discovery of Camelid Antibodies What are Camelid Antibodies? Structure of Camelid Antibodies and Nanobodies Applications of Nanobodies How are Nanobodies Developed? References Discovery of Camelid Antibodies Three decades ago, the discovery1 of a peculiar [...]

January 2022

December 2021

Next Generation Protein Sequencing in Veterinary Medicine and Industry

2022-07-05T14:24:01-04:00December 3rd, 2021|Whitepapers|

Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply

October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2022-04-18T20:15:18-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

September 2021

August 2021

What are Monoclonal Antibodies?

2022-08-17T16:55:40-04:00August 25th, 2021|Articles|

Monoclonal antibodies (mAbs) are homogenous antibodies that bind to a single epitope on an antigen. Kohler and Milstein generated the first mAbs when they developed hybridoma technology in the 1970s. Because of the specificity, homogeneity and unlimited availability, mAbs are valuable reagents used in a variety of important applications including treatment and diagnosis of diseases

July 2021

June 2021

Bispecific Therapeutics Explained

2022-04-25T18:18:31-04:00June 28th, 2021|Articles|

Bispecific therapeutics are monoclonal antibodies that carry a specific antigen-binding capability on each arm. Bispecifics are thus capable of having two specificities that can either double the binding affinity of the antibody toward the same antigen (increased avidity), or can now bind to two targets. Bispecifics are most often described as two types: trispecifics and bispecific T-cell engaged antibodies (BiTE).

March 2021

The Underlying Cause of Medical Diagnostic Invalidation

2021-11-23T09:41:41-05:00March 23rd, 2021|Whitepapers|

In-vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.